• Je něco špatně v tomto záznamu ?

Pharmacological inhibition of eIF2alpha phosphorylation by integrated stress response inhibitor (ISRIB) ameliorates vascular calcification in rats

J. Dong, S. Jin, J. Guo, R. Yang, D. Tian, H. Xue, L. Xiao, Q. Guo, R. Wang, M. Xu, X. Teng, Y. Wu

. 2022 ; 71 (3) : 379-388. [pub] 20220526

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22021455

Vascular calcification (VC) is an independent risk factor for cardiovascular events and all-cause mortality with the absence of current treatment. This study aimed to investigate whether eIF2alpha phosphorylation inhibition could ameliorate VC. VC in rats was induced by administration of vitamin D3 (3×10(5) IU/kg, intramuscularly) plus nicotine (25 mg/kg, intragastrically). ISRIB (0.25 mg/kg·week), an inhibitor of eIF2alpha phosphorylation, ameliorated the elevation of calcium deposition and ALP activity in calcified rat aortas, accompanied by amelioration of increased SBP, PP, and PWV. The decreased protein levels of calponin and SM22alpha, and the increased levels of RUNX2 and BMP2 in calcified aorta were all rescued by ISRIB, while the increased levels of the GRP78, GRP94, and C/EBP homologous proteins in rats with VC were also attenuated. Moreover, ISRIB could prevent the elevation of eIF2alpha phosphorylation and ATF4, and partially inhibit PERK phosphorylation in the calcified aorta. These results suggested that an eIF2alpha phosphorylation inhibitor could ameliorate VC pathogenesis by blocking eIF2alpha/ATF4 signaling, which may provide a new target for VC prevention and treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22021455
003      
CZ-PrNML
005      
20230516114855.0
007      
ta
008      
220907s2022 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934797 $2 doi
035    __
$a (PubMed)35616039
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Dong, Jianlong $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
245    10
$a Pharmacological inhibition of eIF2alpha phosphorylation by integrated stress response inhibitor (ISRIB) ameliorates vascular calcification in rats / $c J. Dong, S. Jin, J. Guo, R. Yang, D. Tian, H. Xue, L. Xiao, Q. Guo, R. Wang, M. Xu, X. Teng, Y. Wu
520    9_
$a Vascular calcification (VC) is an independent risk factor for cardiovascular events and all-cause mortality with the absence of current treatment. This study aimed to investigate whether eIF2alpha phosphorylation inhibition could ameliorate VC. VC in rats was induced by administration of vitamin D3 (3×10(5) IU/kg, intramuscularly) plus nicotine (25 mg/kg, intragastrically). ISRIB (0.25 mg/kg·week), an inhibitor of eIF2alpha phosphorylation, ameliorated the elevation of calcium deposition and ALP activity in calcified rat aortas, accompanied by amelioration of increased SBP, PP, and PWV. The decreased protein levels of calponin and SM22alpha, and the increased levels of RUNX2 and BMP2 in calcified aorta were all rescued by ISRIB, while the increased levels of the GRP78, GRP94, and C/EBP homologous proteins in rats with VC were also attenuated. Moreover, ISRIB could prevent the elevation of eIF2alpha phosphorylation and ATF4, and partially inhibit PERK phosphorylation in the calcified aorta. These results suggested that an eIF2alpha phosphorylation inhibitor could ameliorate VC pathogenesis by blocking eIF2alpha/ATF4 signaling, which may provide a new target for VC prevention and treatment.
650    _2
$a zvířata $7 D000818
650    _2
$a aorta $x metabolismus $7 D001011
650    _2
$a cholekalciferol $x metabolismus $7 D002762
650    12
$a eukaryotický iniciační faktor 2 $7 D015852
650    _2
$a fosforylace $7 D010766
650    _2
$a krysa rodu Rattus $7 D051381
650    12
$a vaskulární kalcifikace $x chemicky indukované $x farmakoterapie $x prevence a kontrola $7 D061205
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jin, Sheng $u Department of Physiology, Hebei Medical University, Shijiazhuang, China $u Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Shijiazhuang, China $u Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Shijiazhuang, China
700    1_
$a Guo, Jingjing $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
700    1_
$a Yang, Rui $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
700    1_
$a Tian, Danyang $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
700    1_
$a Xue, Hongmei $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
700    1_
$a Xiao, Lin $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
700    1_
$a Guo, Qi $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
700    1_
$a Wang, Ru $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
700    1_
$a Xu, Meng $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
700    1_
$a Teng, Xu $u Department of Physiology, Hebei Medical University, Shijiazhuang, China $u Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Shijiazhuang, China $u Hebei Key Laboratory of Neurophysiology, Shijiazhuang, China
700    1_
$a Wu, Yuming $u Department of Physiology, Hebei Medical University, Shijiazhuang, China $u Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Shijiazhuang, China $u Hebei Key Laboratory of Neurophysiology, Shijiazhuang, China
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 71, č. 3 (2022), s. 379-388
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35616039 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y - $z 0
990    __
$a 20220907 $b ABA008
991    __
$a 20230516114852 $b ABA008
999    __
$a kom $b bmc $g 1851685 $s 1172723
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 71 $c 3 $d 379-388 $e 20220526 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK198 $a Pubmed-20220907

Najít záznam

Citační ukazatele

Možnosti archivace